Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of OCT-980 in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa

NCT07408232 is registered in ClinicalTrials.gov with Octant, Inc. as lead sponsor.

NCT NCT07408232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07408232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of OCT-980 in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa
Lead sponsor
Octant, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 10, 2026
Completion date
November 1, 2028
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa